Effects of α-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2263-2269

  Izbicka, Elzbieta ^a   Streeper, Robert T ^a   Yeh, I Tien ^b   Pressley, Oredius ^b   Grant, Michael ^c   Andrews, J Valerie R ^c   Kuhn, Joseph ^c   O'Shaughnessy, Joyce ^c,d  

^a BTNS LLC   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d TEXAS ONCOLOGY   (United States)

Author keywords

difluoromethylornithine; Apoptosis; Biomarker; Breast cancer; DFMO; Invasion; Proliferation

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; EFLORNITHINE; ESTROGEN RECEPTOR; GELATINASE A; GELATINASE B; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; UROKINASE;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; NICK END LABELING; OBSERVATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL PROLIFERATION; EFLORNITHINE; FEMALE; HUMANS; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955075875     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Smith RE and Good BC: Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others. Endocr Relat Cancer 10: 347-357, 2003.
2. Legault S, Poisson R, Franchebois P, Nassif E, Guevin R, Perron L, Thuot C, Enel P and Fisher B: The NSABP. National Surgical Adjuvant Project for Breast and Bowel Cancers. (Definition, role, methodology, therapeutic trials, results, philosophy). Union Med Can 114: 468-473, 500, 1985 (in French).
3. Bevers TB: The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. J Natl Compr Canc Netw 5: 719-724, 2007.
4. Manetta A, Satyaswarcoop PG, Podczaski ES, Hamilton T, Ozols RF and Mortel R: Effect of alpha-difluoromethylornithine (DFMO) on the growth of human ovarian carcinoma. Eur J Gyn Oncol 9: 222-227, 1988.
5. Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, Blanc O, Sjoerdsma A and Baylin SB: Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine - an inhibitor of polyamine biosynthesis. J Clin Oncol 2: 124-130, 1984. (Pubitemid 14152455)
6. Fabian CJ and Kimler BF: Breast cancer chemoprevention: current challenges and a look toward the future. Clin Breast Cancer 3: 113-124, 2002.
7. Ellis RJ, Fabian CJ, Kimler BF, Tawfik O, Mayo MS, Decelis CR, Jewell WR, Connor C, Modrell C, Praeger M, McGinness M, Mehta R and Fruehauf JP: Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens. Breast Cancer Res Treat 71: 95-102, 2002.
8. Manni A, Washington S, Hu X, Griffith JW, Bruggeman R, Demers LM, Mauger D and Verderame MF: Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells. Clin Exp Metastasis 22: 255-263, 2005.
9. Love RR, Carbone PP, Verma AK, Gilmore D, Carey P, Tutsch KD, Pomplun M and Wilding G: Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst 85: 732-737, 1993. (Pubitemid 23133595)
10. Fabian CJ, Kimler BF, Brady DA, Mayo MS, Chang CH, Ferraro JA, Zalles CM, Stanton AL, Masood S, Grizzle WE, Boyd NF, Arneson DW and Johnson KA: A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 8: 3105-3117, 2002.
11. O'Shaughnessy JA, Demers LM, Jones SE, Arseneau J, Khandelwal P, George T, Gersh R, Mauger D and Manni A: Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients. Clin Cancer Res 5: 3438-3444, 1999.
12. Levin, VA, Prados MD, Yung WK, Gleason MJ, Ictech S and Malec M: Treatment of recurrent gliomas with eflornithine. J Natl Cancer Inst 84: 1432-1437, 1992.
13. Buckner JC, Burch PA, Cascino TL, O'Fallon JR and Scheithauer BW: Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma. J Neuro-oncol 36: 65-70, 1998. (Pubitemid 28230654)
14. Yeh IT and Luduena RF: The betaII isotype of tubulin is present in the cell nuclei of a variety of cancers. Cell Motil Cytoskel 57: 96-106, 2004
15. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
16. Stabellini G, Moscheni C, Gagliano N, Dellavia C, Calastrini C, Ferioli ME and Gioia M: Depletion of polyamines and increase of transforming growth factor-beta 1, c-myc, collagen-type I, matrix metalloproteinase-1, and metalloproteinase-2 mRNA in primary human gingival fibroblasts. J Periodontol 76: 443-449, 2005.
17. Graham CH, Postovit LM, Park H, Canning MT and Fitzpatrick TE: Adriana and Luisa Castellucci award lecture 1999: role of oxygen in the regulation of trophoblast gene expression and invasion. Placenta 21: 443-450, 2000.
18. Lash GE, Postovit LM, Matthews NE, Chung EY, Canning MT, Pross H, Adams MA and Graham CH: Oxygen as a regulator of cellular phenotypes in pregnancy and cancer. Can J Physiol Pharmacol 80: 103-109, 2002.
19. Matters GL, Manni A and Bond JS: Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells. Clin Exp Metastasis 22: 331-339, 2005.
20. Nemoto T, Kubota S, Ishida H, Murata N and Hashimoto D: Ornithine decarboxylase, mitogen-activated protein kinase and matrix metalloproteinase-2 expressions in human colon tumors. World J Gastroenterol 11: 3065-3069, 2005.
21. Thupari JN, Pinn ML and Kuhajda FP: Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 285: 217-223, 2001.
22. Zhou W, Simpson PJ, McFadden JM, Townsend CA, Medghalchi SM, Vadlamudi A, Pinn ML, Ronnett GV and Kuhajda FP: Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res 63: 7330-7337, 2003. (Pubitemid 37413474)
23. Fabian CJ, Kimler BF, Anderson J, Tawfik OW, Mayo MS, Burak WE Jr, O'Shaughnessy JA, Albain KS, Hyams DM, Budd GT, Ganz PA, Sauter ER, Beenken SW, Grizzle WE, Fruehauf JP, Arneson DW, Bacus JW, Lagios MD, Johnson KA and Browne D: Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clin Cancer Res 10: 5403-5417, 2004.
24. Prasad R, Boland GP, Cramer A, Anderson E, Knox WF and Bundred NJ: Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer 98: 2539-2546, 2003.